Delving into the Latest Updates on Biospring Medical Co., Ltd. with Synapse

Overview

Tags

Respiratory Diseases

Mesenchymal stem cell therapy

Disease domain score

A glimpse into the focused therapeutic areas

No Data

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Top 5 Drug Type	Count

Mesenchymal stem cell therapy	1

The goal of this clinical trial is to explore the safety, tolerability, and efficacy in study intervention, MatriPlax, in subjects with Acute Respiratory Distress Syndrome (ARDS). MatriPlax contains placenta choriodecidual membrane-derived Mesenchymal Stem Cells (pcMSCs). Participants will receive two doses of MatriPlax on Day 1 and Day 4 and conduct efficacy and safety evaluations until 12 months after treatment or withdrawal from the study.

Start Date01 Dec 2023

Sponsor / Collaborator

Biospring Medical Co., Ltd.

100 Clinical Results associated with Biospring Medical Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Biospring Medical Co., Ltd.

Login to view more data

100 Deals associated with Biospring Medical Co., Ltd.

Login to view more data

100 Translational Medicine associated with Biospring Medical Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 24 Apr 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

1

Login to view more data